Literature DB >> 23985239

[Surgical treatment of gastric cancer: focus on centralisation and laparoscopic resections].

Leonie Haverkamp1, Jelle P Ruurda, Pieter C van der Sluis, Richard van Hillegersberg.   

Abstract

Approximately 2000 patients are diagnosed with gastric carcinoma in the Netherlands each year; about 500 will be eligible for curative surgical treatment. The 5-year survival rate after therapy aimed at curing the condition is 45%, which can increase by an average of 10% if perioperative chemotherapy is added to the treatment regimen. Surgical treatment consists of a distal or total gastrectomy with spleen-preserving lymphadenectomy. Centralising this type of treatment leads to less postoperative mortality and better oncological outcomes. There are indications that laparoscopic surgery can accelerate postoperative recovery time. There are insufficient long-term data on outcomes of laparoscopic surgery to date to be able to conclude whether the laparoscopic or open approach to total gastric resection is preferable.

Entities:  

Mesh:

Year:  2013        PMID: 23985239

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  3 in total

1.  Safety and feasibility of minimally invasive gastrectomy during the early introduction in the Netherlands: short-term oncological outcomes comparable to open gastrectomy.

Authors:  H J F Brenkman; J P Ruurda; R H A Verhoeven; R van Hillegersberg
Journal:  Gastric Cancer       Date:  2017-02-09       Impact factor: 7.370

2.  A High Lymph Node Yield is Associated with Prolonged Survival in Elderly Patients Undergoing Curative Gastrectomy for Cancer: A Dutch Population-Based Cohort Study.

Authors:  Hylke J F Brenkman; Lucas Goense; Lodewijk A Brosens; Nadia Haj Mohammad; Frank P Vleggaar; Jelle P Ruurda; Richard van Hillegersberg
Journal:  Ann Surg Oncol       Date:  2017-02-28       Impact factor: 5.344

3.  Evaluation of the Implementation of FDG-PET/CT and Staging Laparoscopy for Gastric Cancer in The Netherlands.

Authors:  Emma C Gertsen; Alicia S Borggreve; Hylke J F Brenkman; Rob H A Verhoeven; Erik Vegt; Richard van Hillegersberg; Peter D Siersema; Jelle P Ruurda
Journal:  Ann Surg Oncol       Date:  2020-09-08       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.